Peroxisome Proliferator-activated Receptor-γ (PPARγ) Agonist Improves Coronary Artery Endothelial Function in Diabetic Patients with Coronary Artery Disease

被引：22

作者：

Yu, J. ^{[1
]}

Zhang, Z. ^{[2
]}

Li, Z. ^{[1
]}

Feng, X. ^{[1
]}

He, L. ^{[1
]}

Liu, S. ^{[1
]}

Mao, J. ^{[1
]}

Wang, G. ^{[1
]}

Wang, X. ^{[1
,3
,4
]}

机构：

[1] Peking Univ, Hosp 3, Dept Cardiovasc Med, Beijing 100191, Peoples R China

[2] Peking Univ, Hosp 3, Dept Cardiosurg Med, Beijing 100191, Peoples R China

[3] Peking Univ, Hlth Sci Ctr, Minist Educ, Dept Physiol, Beijing 100191, Peoples R China

[4] Peking Univ, Hlth Sci Ctr, Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing 100191, Peoples R China

来源：

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2010年 / 38卷 / 01期

关键词：

CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL FUNCTION; ROSIGLITAZONE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-gamma (PPAR gamma) AGONIST; CORONARY FLOW VELOCITY RESERVE; SMOOTH-MUSCLE-CELLS; NONDIABETIC PATIENTS; INFLAMMATORY MARKERS; DENSITY-LIPOPROTEIN; INSULIN-RESISTANCE; METABOLIC SYNDROME; PIOGLITAZONE; ATHEROSCLEROSIS; ROSIGLITAZONE; EXPRESSION;

D O I：

10.1177/147323001003800110

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The aim of this study was to assess the effect of rosiglitazone on endothelial function of the coronary arteries and on plasma levels of inflammatory markers in diabetic patients with coronary artery disease (CAD). Fifty-six patients with type 2 diabetes and CAD were randomized to receive either rosiglitazone (4 mg/day) or a control for 12 weeks. The coronary flow velocity reserve (CFVR) was assessed using transthoracic Doppler echocardiography at baseline and after 12 weeks. After 12 weeks of rosiglitazone treatment, plasma levels of C-reactive protein were significantly decreased and the median CFVR was significantly increased compared with baseline levels and compared with the control group. These results suggest that, in addition to its beneficial metabolic effects, rosiglitazone, via its anti-inflammatory effects, may improve endothelial function of the coronary arteries in patients with diabetes and CAD.

引用

页码：86 / 94

页数：9

共 25 条

[21] Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty [J].

Wang, G ;

Wei, JR ;

Guan, YF ;

Jin, N ;

Mao, JM ;

Wang, X .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (05) :590-597

[22] Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease [J].

Wang, Guang ;

Zhang, Zhe ;

Yu, Jie ;

Zhang, Fuchun ;

He, Liyun ;

Wei, Jinru ;

Mao, Jieming ;

Wang, Xian .

PPAR RESEARCH, 2008, 2008

[23] Modulation of PPARγ activity with pharmaceutical agents:: Treatment of insulin resistance and atherosclerosis [J].

Wang, MH ;

Tafuri, S .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 89 (01) :38-47

[24] The peroxisome proliferator-activated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance [J].

Werner, Christian ;

Kamani, Christel Hermann ;

Gensch, Christoph ;

Boehm, Michael ;

Laufs, Ulrich .

DIABETES, 2007, 56 (10) :2609-2615

[25] Peroxisome proliferator -: activate receptor γ agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease [J].

Yu, Jie ;

Jin, Nan ;

Wang, Guang ;

Zhang, Fuchun ;

Mao, Jieming ;

Wang, Xian .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2007, 56 (10) :1396-1401

← 1 2 3 →